Product Information
PERAMPANEL 8 MG TABLET is a generic product labeled by Novadoz Pharmaceuticals LLC, priced at $18.3765 per EA under NDC 72205022430. Its NADAC has been published 36 times since Jan 28, 2026.
FDA first approved this application on Nov 25, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 mg/1
Manufacturer
Novadoz Pharmaceuticals LLCNDC
72205022430
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PERAMPANELApproval Type
Generic (ANDA)
FDA Application
ANDA218178FDA Approved
11/25/2025
TE Code
AB
On Market Since
11/25/2025
Pharmacological Classes
Price Statistics
The NADAC for PERAMPANEL 8 MG TABLET has been published 36 times since Jan 28, 2026, and over the history we have for it it has declined 43.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $18.3765 per EA |
|---|---|
| All-time high | $32.4370 (Mar 11, 2026) |
| All-time low | $18.3765 (Sep 23, 2026) |
| 52-week high | $32.4370 |
| 52-week low | $18.3765 |
| Median price | $19.7674 |
| Average price | $23.7258 |
| Largest weekly change | -19.9% (May 20, 2026) |
| Weeks tracked | 36 |
| Tracking since | Jan 28, 2026 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novadoz Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Perampanel market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Noncompetitive AMPA Glutamate Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PERAMPANEL 8 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PERAMPANEL 8 MG TABLET, manufactured by Novadoz Pharmaceuticals LLC, is $18.3765 per EA (NDC 72205022430), effective Sep 30, 2026.
How has the price of PERAMPANEL 8 MG TABLET changed over time?
Over the history we have for it, the NADAC for PERAMPANEL 8 MG TABLET has declined 43.3%. It has been tracked across 36 weekly CMS publications since Jan 28, 2026.
What are the highest and lowest recorded NADAC prices for PERAMPANEL 8 MG TABLET?
Since Jan 28, 2026, the NADAC for PERAMPANEL 8 MG TABLET has ranged from a low of $18.3765 (Sep 23, 2026) to a high of $32.4370 (Mar 11, 2026), with a median of $19.7674 per EA.
Are there cheaper alternatives to PERAMPANEL 8 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PERAMPANEL 8 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PERAMPANEL 8 MG TABLET?
PERAMPANEL 8 MG TABLET (NDC 72205022430) is labeled by Novadoz Pharmaceuticals LLC, and CMS classifies it as a generic product.